Palbociclib Isethionate
99%
- Product Code: 52583
CAS:
827022-33-3
| Molecular Weight: | 573.66 g./mol | Molecular Formula: | C₂₄H₂₉N₇O₂C₂H₆O₄S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD22666589 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | room temperature |
Product Description:
Palbociclib Isethionate is primarily used in the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is often prescribed in combination with other hormonal therapies, such as letrozole or fulvestrant, to enhance its effectiveness. The drug works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which play a crucial role in cell cycle progression. By blocking these kinases, it helps to slow down or halt the proliferation of cancer cells. This targeted approach makes it a valuable option for patients who have not responded well to other treatments. Its use has shown significant improvement in progression-free survival, making it a key component in the management of advanced breast cancer.
Product Specification:
| Test | Specification |
|---|---|
| Purity | 98.5 100% |
| Appearance | WHITE TO BEIGE POWDER |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.050 | 10-20 days | £112.86 |
+
-
|
| 0.100 | 10-20 days | £218.03 |
+
-
|
| 0.500 | 10-20 days | £782.55 |
+
-
|
Palbociclib Isethionate
Palbociclib Isethionate is primarily used in the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is often prescribed in combination with other hormonal therapies, such as letrozole or fulvestrant, to enhance its effectiveness. The drug works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which play a crucial role in cell cycle progression. By blocking these kinases, it helps to slow down or halt the proliferation of cancer cells. This targeted approach makes it a valuable option for patients who have not responded well to other treatments. Its use has shown significant improvement in progression-free survival, making it a key component in the management of advanced breast cancer.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
£0.00
£0.00
Total :